Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1992-10-20
1995-10-31
Wityshyn, Michael G.
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
424 851, 514 12, 514 21, 530351, A61K 4505, A61K 3700
Patent
active
054627311
ABSTRACT:
The use of interleukin-6 and/or salts, functional derivatives, muteins or active fractions thereof, in the treatment of chronic lymphocytic leukemia and B-cell lymphomas, as well as such use together with the soluble interleukin-6 receptor, to pharmaceutical compositions and to a method of treating chronic lymphocytic leukemia or B-cell lymphomas.
REFERENCES:
patent: 5087448 (1992-02-01), Burstein
patent: 5126325 (1992-06-01), Kishimoto et al.
Chen, L. et al., "Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-.beta..sub.2 ", Proc. Natl. Acad. Sci USA 85:8037-8041 (Nov. 1988).
Freeman, G. et al., "Interleukin 6 Gene Expression in Normal and Neoplastic B Cells", J. Clin. Invest 83 No. 5:1512-1518 (May 1989).
Chronic Lymphocytic Leukemica: New Insights into Biology and Therapy; Annals of Internal Medicane, 1990; vol. 113, No. 7, pp. 525-539.
British Journal of Haematology, 1984, 57, 105-111; Kay et al: Defective Expression of T Cell Antigens in Chronic Lymphocytic Leukemia: Relationship to T Cell Dysfunction.
Blood, vol. 57, No. 3 (Mar.), 1981; Neil Kay: Abnormal T-Cell Sybpopulation Function in CLL: Excessive Suppressor (Tr) and Deficient Helper (Tu) Activity with Respect to B-Cell Proliferation.
The Journal of Immunology, vol. 129, No. 5, Nov. 1992; pp. 2305-2312; "Abnoraml T Lymphocyte Subpopulations in Patients with B Cell Chronic Lymphocytic Leukemia: An Analysis by monoclonal Antibodies". Chris D. Platsoucas et al.
Blood, vol. 54, No. 2 (Aug.) 1979; Kay et al: T-Cell Subpopulations in Chronic Lymphocytic Leukemia: Abnormalities of Distribution and in in Vitro Receptor Maturation.
Americal Journal of Hematology 30:61-67(1989); Alan R. Liss, Inc.: Malignant Chronic Lymphocytic Leukemia B Cells Eleaborate Soluble Factors that Down-Regulate T-Cell and NK Function. Burton et al.
The Journal of Immunology, vol. 131, No. 2, Aug. 1983; Falkoff et al: The Effects of Interleukin 1 on Human B Cell Activation and Proliferation.
The New England Journal of Medicine, Juliusson et al, Sep. 13, 1990; Prognostic Subgroupes in B-Cell Chronic Lymphocytic Leukemia Defined by Specific Chromosomal Abnormalities.
J. Exp. Med., The Rockefeller Univ. Press, vol. 165, Mar. 1987; Brief Definitive Report; Identification of The Human 26-kD Protein, Interferon B.sub.2 (IFN-B.sub.2), As A B Cell Hybridomas/Plasmacytoma Growth Factor Induced by Interleukin 1 and Tumor Necrosis Factor.
J. Exp. Med., The Rockefeller Univ. Press, vol. 167, Feb. 1988, 332-344; Muraguchi et al: The Essential Role B Cell Stimulatory Factor 2 (BSF-2/IL-6) For the Terminal Differentiation of B Cells.
Nature, vil. 332, Mar. 3, 1988; pp. 83-84; Autocrine Generation and Requirement of BSF-2/IL-6 For Human Multiple Myelomas. Kawano et al.
The Lancet, Apr. 30, 1988; Cordingley et al.: Tumor Necrosis Factor as an Autocrine Tumour Growth Factor for Chronic B-Cell Malignancies.
Blood, vol. 73, No. 5 (Apr.), 1989; pp. 1242-1246; Digel et al: Tumor Necrosis Factor Induces Proliferation of Neoplastic B Cells from Chronic Lymphocytic Leukemia.
Blood, vol. 73, No. 5 (Apr.), 1989, pp. 1279-1284; Biondi et al.; Constitutive Expression of the Interleukin-6 Gene in Chronic Lymphocytic Leukemia.
Journal of Hematologie, (1988), pp. 317-318; ACM Bianchi; Dept. of Haematology: Effects of Tumor Necrosis Factor and a Interferon on Chronic B Cell Malignancies.
J. Exp. Med., The Rockfeller Univ. Press, vol. 172, Dec. 1990; pp. 1729-1734; Effects of Interferon .alpha. on Autocrine Growth Factor Loops in B Lymphoroliferative Disorders; Heslop et al.
The Journal of Immunology, vol. 140, No. 12, Jun. 15, 1988; pp. 4329-4336; Tosato et al.: Stimulation of EBV-Activated Human B Cells by Monocytes and Monocyte Products.
Cell, vol. 58, 573-581, Aug. 11, 1989; Taga et al.: Interleukin-6 Triggers the Association of its Receptor with a Possible Signal Transducer, gp130.
Journal of Immunological Methods, 33(1980) 323-336; Madselen et al.: Isolation of Human T and B Lymphocytes by E-Rosette Gradient Centrifugation. Characterization of the Isolated Subpopulations.
Cellular Immunology 58, 426-435 (1981); Fischer et al.: Tumor Cell Killing by Freshly Isolated Peripheral Blood Monocytes.
The Journal of Immunology, vol. 143, 3517-3523, No. 11, Dec. 1, 1989; IL-6 Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor Production in Cultured Human Monocytes, U937 Cells, and in Mice. by Aderka et al.
Blood, vol. 75, No. (Jan. 1), 1990; pp. 40-47; Schindler et al.: Correlation and Interactions in the Production of Interleukin-6 (IL-6), Il-1; and Tumor Necrosis Factor (TNF) in Human Blood Mononuclear Cells: IL-6 Suppresses IL-1 and TNF.
Cancer Research 51, pp. 5602-5607, Oct. 1991; Aderka et al.: Increased Serum Levels of Soluble Receptors for Tumor Necrosis in Cancer Patients.
Lahat et al, Clin. Exp. Immunol., vol. 85, No. 2, pp. 302-306, Aug. 1991.
Schindler et al, Blood, vol. 75, No. 1, pp. 40-47, Jan. 1, 1990.
Aderha et al, Blood, vol. 81, No. 8, pp. 2076-2084, Apr. 15, 1993.
Hsu et al, American Journal of Pathology, vol. 141, No. 4, pp. 915-923, Oct. 1992.
Aguilar-Santelises, Clin. Exp. Immunol, vol. 84, No. 3, pp. 422-428, Jun. 1991.
Aderka Dan
Maor Yasmin
Revel Michel
Wallach David
Mohamed Abdela
Wityshyn Michael G.
Yeda Research and Development Company Ltd.
LandOfFree
Use of IL-6 for the treatment of chronic lymphocyte leukemia (CL does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of IL-6 for the treatment of chronic lymphocyte leukemia (CL, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of IL-6 for the treatment of chronic lymphocyte leukemia (CL will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1770612